Search | Clinical Trials Finder

Conditions: Seasonal Allergic Rhinitis
Interventions: 0.15% azelastine hydrochloride 1644 mcg daily, 0.1% azelastine hydrochloride 1096 mcg daily, Placebo; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 29
States / cities: Oxford, Alabama • Encinitas, California • Los Angeles, California + 25 more

Conditions: Seasonal Allergic Rhinitis (SAR)
Interventions: GSP 301 NS, GOM-NS, GMM-2 NS, GSP 301 placebo NS; Drug
Lead sponsor: Glenmark Specialty S.A.; Industry
Eligibility: 12 Years and older
Enrollment: 1,176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 43
States / cities: Mission Viejo, California • Orange, California • San Diego, California + 33 more

Conditions: Seasonal Allergic Rhinitis
Interventions: levocetirizine dihydrochloride, placebo; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 38
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 35 more

Conditions: Rhinitis, Allergic, Seasonal
Interventions: AHIST NDC#58407-012-01; Drug
Lead sponsor: Magna Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 60 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Perennial Allergic Rhinitis With Seasonal Variation
Interventions: allergen immunotherapy; Other
Lead sponsor: United Allergy Services; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Allergic Rhinitis
Interventions: Ibuprofen, Fluticasone propionate, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Seasonal Allergic Rhinitis
Interventions: Orotic acid and Glutathione-(Nutritional Supplements); Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Seasonal Allergic Rhinitis
Interventions: ACT-129968, Placebo, Cetirizine; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 12 Years to 76 Years
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more

Conditions: Hay Fever, Perennial Allergic Rhinitis
Interventions: Ciclesonide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Long Beach, California • Normal, Illinois • San Antonio, Texas

Conditions: Allergic Conjunctivitis
Interventions: REGN5713, REGN5715, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Andover, Massachusetts • Lincoln, Nebraska

Conditions: Influenza Infection
Interventions: VRC-FLUNPF099-00-VP (H1ssF_3928); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Seasonal Allergic Rhinitis, Hayfever
Interventions: Beclomethasone dipropionate HFA Nasal Aerosol, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 487 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 26
States / cities: Mission Viejo, California • San Diego, California • Colorado Springs, Colorado + 22 more

Conditions: Allergic Rhinitis
Interventions: Placebo, Allegra, Allegra-D, PF-03654746; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Rhinitis, Allergic, Seasonal
Interventions: Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals), Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray, Placebo; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 12 Years and older
Enrollment: 727 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more

Conditions: Rhinitis, Allergic, Seasonal
Interventions: Fluticasone furoate and fexofenadine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 6
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more

Conditions: Allergy
Interventions: ALK Ragweed Tablet; Biological
Lead sponsor: ALK-Abelló A/S; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Seasonal Allergic Rhinitis
Interventions: Nasal CO2, Inactive Placebo Gas; Drug
Lead sponsor: Capnia, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Allergic Rhinitis
Interventions: Placebo, VAK694, Fluticasone; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Duncansville, Pennsylvania

Conditions: Rhinitis, Allergic, Seasonal
Interventions: PQ Grass, Active Placebo, Standard Placebo; Biological · Drug
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 8
States / cities: Lexington, Kentucky • White Marsh, Maryland • Ocean Township, New Jersey + 5 more

Conditions: Seasonal Allergic Rhinitis, SAR
Interventions: BDP HFA, Placebo nasal aerosol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 715 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 45
States / cities: Oxford, Alabama • Bell, California • Costa Mesa, California + 40 more

Conditions: Allergic Rhinitis, Conjunctivitis
Interventions: REGN5713, REGN5714, REGN5715, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 14
States / cities: Bangor, Maine • Baltimore, Maryland • Plymouth, Minnesota + 11 more

Conditions: Rhinitis, Allergic, Seasonal
Interventions: GW685698X Aqueous Nasal Spray; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Woodstock, Georgia

Conditions: Seasonal Allergic Rhinitis
Interventions: Ciclesonide nasal aerosol 37 mcg, ciclesonide nasal aerosol 74 mcg, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 847 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 66
States / cities: Little Rock, Arkansas • Baldwin Park, California • Costa Mesa, California + 49 more

Conditions: Seasonal Allergic Rhinitis
Interventions: fexofenadine HCl; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Search by objective public record fields.

A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies

Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)

A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

Study of AHIST in Seasonal Allergic Rhinitis Patients

The Efficacy & Safety of the UAS Immunotherapy Protocol

A Study To Explore The Effect On Inflammatory Markers After Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis And The Effect Of A Single Dose Of Ibuprofen Or Fluticasone Propionate On The Allergen Response.

Effects of Orotic Acid Derivatives With or Without Glutathione on Allergic Rhinitis

Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis

Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)

Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy

Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults

Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR

A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge

A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine

Safety of ALK Ragweed Tablet

The Effect of Nasal Carbon Dioxide (CO2) Used As-Needed in the Symptomatic Treatment of Seasonal Allergic Rhinitis

Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis

An Exploratory Study of PQ Grass 27600 SU

Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies

Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

Study In Adolescent And Adult Subjects 12 Years Of Age And Older With Seasonal Allergic Rhinitis To Assess Onset of Action

A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)

Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel